Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF2 | P09038 | 1/20 | 0.45 |
| ▸ | M6PR | P20645 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | IDUA | P35475 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067350 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL18030805 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL13523545 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL24212702 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL7152405 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL23343942 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL13478949 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL21134565 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL21586585 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL14208597 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137619-A1 | ANTI-CLAUDIN, BIS-BENZIMID AZOLE STING AGONIST IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024129956-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024110905-A1 | ANTI-CEA ANTIBODY DRUG CONJUGATES AND METHODS OF USE | BEIGENE, LTD. (KY) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024086744-A2 | COMPOSITIONS AND USES THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023076599-A1 | TLR AGONIST IMMUNOCONJUGATES WITH CYSTEINE-MUTANT ANTIBODIES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023275715-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | PFIZER INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022234287-A1 | IMIDAZOPYRIDAZINE DERIVATIVES USEFUL AS TRK INHIBITORS | BENEVOLENTAI BIO LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022204536-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2008052086-A1 | BENZODIOXANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008052087-A1 | CHROMANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007141513-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | NOVABIOTICS LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007005568-A1 | A-[(E)-2-(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPTHALENYL)-1-PROPENYL]BENZOIC ACID ANALOGS AND METHOD OF MANUFACTURE AND AND USE THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20060241176-A1 | Dihydrobenzofuran derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20060241176-A1 | Dihydrobenzofuran derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129282-A1 | Pharmaceutical treatments and compositions | HSD3B1, HSD3B2, HSD17B1 | FGF2 2402/4885M6PR 4739/4885AKT1 2629/4885 |
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | SERPINB1, ELANE, CELA1 | FGF2 2794/4885M6PR 1639/4885AKT1 4243/4885 |
| US-20060241176-A1 | Dihydrobenzofuran derivatives and uses thereof | HTR1F, HTR2C, HTR1A | FGF2 1202/4885M6PR 1246/4885AKT1 1861/4885 |
| US-20070275936-A1 | Formulations and Treatment Methods | HSD3B1, HSD17B1, HSD17B3 | FGF2 2262/4885M6PR 4669/4885AKT1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.